Deployment of ACT antimalarials for treatment of malaria: challenges and opportunities.
Deployment of ACT antimalarials for treatment of malaria: challenges and opportunities.
复制标题
DOI：
10.1186/1475-2875-7-s1-s7
复制
发表时间：
2008-12-11
期刊：
影响因子：
3
通讯作者：
Staedke SG
中科院分区：
文献类型：
--
作者：
Whitty CJ;Chandler C;Ansah E;Leslie T;Staedke SG
长期以来，现有抗疟药物单一疗法的有效性不断下降且没有明确的替代方案，非洲和亚洲的大多数疟疾流行国家已采用青蒿素联合疗法（ACT）作为抗疟药物政策。已有多种 ACT 药物，其他药物正在研发中。如果目标正确，它们有可能大幅降低疟疾死亡率。现在的主要挑战是将药物送到合适的人手中。目前的证据表明，大多数需要这些药物的人并没有得到它们。同时，服用抗疟药的人中很大一部分实际上并未患有疟疾。财务和其他障碍意味着，在许多情况下，大多数疟疾患者，特别是最贫困的人，无法获得正规医疗保健，因此通过这种途径提供免费抗疟药物的影响有限。 ACT 的较高成本创造了假药市场。解决这些问题是现在的当务之急。这篇综述概述了当前的证据、可能的解决方案和研究重点。
Following a long period when the effectiveness of existing mono-therapies for antimalarials was steadily declining with no clear alternative, most malaria-endemic countries in Africa and Asia have adopted artemisinin combination therapy (ACT) as antimalarial drug policy. Several ACT drugs exist and others are in the pipeline. If properly targeted, they have the potential to reduce mortality from malaria substantially. The major challenge now is to get the drugs to the right people. Current evidence suggests that most of those who need the drugs do not get them. Simultaneously, a high proportion of those who are given antimalarials do not in fact have malaria. Financial and other barriers mean that, in many settings, the majority of those with malaria, particularly the poorest, do not access formal healthcare, so the provision of free antimalarials via this route has only limited impact. The higher cost of ACT creates a market for fake drugs. Addressing these problems is now a priority. This review outlines current evidence, possible solutions and research priorities.